Field Trials Sample Clauses

Field Trials. The parties shall conduct field trials for the Products ("Field Trials") pursuant to the Field Trial Agreement attached hereto as Exhibit B.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Field Trials. Seller will deliver Modems for Buyer to conduct field trials on or prior to September 30, 1999. If the Modems have mechanical or electrical failures in excess of 4% during Buyer field trial then Seller shall immediately stop delivery of Modems to the Novatel [***] Confidential treatment has been requested for the bracketed portions. The confidential redacted portion has been omitted and filed separately with the Securities and Exchange Commission.
Sample 1Sample 2See All (4)
Field Trials. Within the [] months following the Turnover Date, at ------------ MIKN's request, HOC shall allow MIKN to install for field trial and evaluation purposes TT/ST System Tables and TT/SJ System Tables comprising at least []. MIKN shall be HOC's exclusive source of supply for all hardware and software comprising the TT/ST System Tables and TT/SJ System Tables for such field trial and shall be HOC's exclusive source for servicing and maintaining such hardware and software. HOC shall permit the TT/ST System Tables installed in accordance with this Section 6.2 to remain installed at the foregoing HOC Properties for such period of time as may be reasonably necessary for MIKN to obtain any required regulatory approvals in each respective jurisdiction. MIKN shall be responsible for, shall pay for and shall exert commercially reasonable efforts to obtain such regulatory approvals as expeditiously as reasonably possible. HOC shall pay for the TT/ST System Tables and TT/SJ System Tables installed under this Section 6.2 in accordance with the provisions in Section 7. HOC shall cooperate with MIKN in operating and presenting the TT/ST System Tables to regulatory authorities to facilitate prompt approval.
Sample 1Sample 2Sample 3
Field Trials. Where Buyer and Seller agree to conduct field trials using Buyer's network and Prototype Products, should FCC type acceptance or other regulatory approval not have been granted for the Prototype or Pre-production Products, Seller, at its cost and with appropriate support from Buyer in Buyer's discretion, shall promptly seek and diligently prosecute, a request for expedited approval or an interim waiver to meet regulatory requirements. In connection with such field trials, at no charge to Seller, Buyer shall provide Seller with a commercially reasonable number of SIMs xxx the purpose of conducting such field trials. The SIMs xx be provided to Seller shall be enabled for use in Buyer's home network and for roaming in other networks. The reasonable and customary expenses incurred by Seller in performing such tests shall be borne by Seller.
Sample 1Sample 2
Field Trials. The Contractor shall construct wood forms at least 6 inches thick by 2 feet by 2 feet in size. The Contractor shall have each proposed nozzle operator make test panels on two vertical wood forms. The test panels shall be cured according to AASHTO T 23, without immersing the panels. At least one of the test panels shall include reinforcement.
Sample 1Sample 2
Field Trials. For Royalty Bearing Products Placed for field trial purposes, License Fees will be reported and paid as described above. However, if field trial units are removed from service or otherwise returned to Licensee within 60 days of the installation, and no remuneration has been paid by Licensees' End User for such units, a corresponding credit of the License Fee will be reported and applied against License Fees owed to Licensor.
Sample 1
Field Trials. Corrosion monitoring of two bridges rehabilitated with patch repairs and application of corrosion inhibitors. Corrosion monitoring of samples stored in a marine exposure facility. Task 13.6: Specifications. Preparation of specifications for the use of CI for maintenance. Deliverables Deliverable D17: Test report on effectiveness of corrosion inhibitor in laboratory trials Date due: Month 24 Deliverable D21: Test report on effectiveness of corrosion inhibitor in field trials Date due: Month 30 Deliverable D25: Specification for the use of CI for maintenance of highway structures Date due: Month 33 Milestones and criteria Milestone M3: Decision on the properties of the concretes to be used in the laboratory Date due: Month 6 trials and field exposure trial. Selection of the materials. Interrelation with other work packages WP 12, WP 16
Sample 1
AutoNDA by SimpleDocs
Field Trials. Distributor agrees to take full responsibility of any field trial that may be required in the Territory. In case RiT decides to perform such a trial, the Distributor commits to arrange all the logistics and approvals for it and commits to include it in the business plan. Main candidates for this work plan are (list of telephone company names): MGTS____________________________________________ _________________________________________________
Sample 1
Field Trials. With respect to each Collaboration SNP Set: (i) within [* * *]([* * *]) [* * *] from delivery to Bayer of the SNP Computational Summary Report of such Collaboration SNP Set, Bayer shall initiate an introgression process into Wheat with respect to such Collaboration SNP Set; (ii) within [* * *] ([* * *]) [* * *], or within a period of time as discussed in and advised by the Research Committee, from delivery to Bayer of the SNP Computational Summary Report of such Collaboration SNP Set, Bayer shall complete the development of an SNP Assay with respect to such Collaboration SNP Set; and (iii) [* * *].
Sample 1

Related to Field Trials

  • Field Trips Orange COUNTY funds may not be used to support any overnight and/or out of Central Florida travel, unless approved by the COUNTY’S Manager of the CCC or designee in advance. The AGENCY must have on file for field trip(s) that each participant, adult or minor, must have a signed release of liability form releasing the COUNTY from any liability. If the participant is a minor, the release must be signed by a parent/guardian. Central Florida is defined as Orange, Osceola, Seminole, Brevard, Lake, Polk, and Volusia Counties.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Trials The Ship shall run the following test and trials:

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Field The term “

Time is Money Join Law Insider Premium to draft better contracts faster.